NUVB
NYSENuvation Bio Inc.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$0
2023
$7.9M
2024
$62.9M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$62.9M
Net Income$-204.6M
Gross Profit—
Oper Income$-213.1M
EPS (dil)$-0.60
Rev/sh$0.18
FCF/sh—
Book/sh$0.88
Gross M—
Oper M-338.7%
Profit M-325.3%
FCF M—
ROE-66.9%
ROA-34.4%
ROIC-112.8%
R&D/Rev183.0%
Rev Y/Y699.0%
Rev 3Y CAGR—
EPS Y/Y71.6%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+27.1%
Current Ratio6.95
Quick Ratio6.81
Debt/Eq0.15
Int Coverage-15.6×
Net Debt$116.9M cash
Total Debt$47.2M
Cash & Eq$164.1M
Total Assets$594.8M
Oper CF$-173.4M
Capex—
Free CF—
Buybacks—
Equity$305.7M
Liabilities$289.1M
Shs Outstand0.35B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 3 FY| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $0 | $7.9M | $62.9M |
| Gross Profit | $0 | $795,000 | — |
| Operating Income | $-99.8M | $-592.6M | $-213.1M |
| Net Income | $-75.8M | $-567.9M | $-204.6M |
| Diluted EPS | $-0.35 | $-2.11 | $-0.60 |
| Operating Cash Flow | $-68.0M | $-130.4M | $-173.4M |
| Free Cash Flow | — | — | — |
COMMUNITY · $NUVB0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.